Time to rethink high-density lipoprotein?

Heart

Volumn 94, Issue 6, 2008, Pages 692-694

  Wild, Sarah ^a   Byrne, Christopher D ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [3 [4,5 DIHYDRO 1 (4 METHYLBENZYL) 5 OXO 1H 1,2 4 TRIAZOL 3 YL]PROPYL]PHENOXY] 2 METHYLPROPIONIC ACID; APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE; ATORVASTATIN; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLACEBO; SPHINGOSINE 1 PHOSPHATE; TORCETRAPIB; TRIACYLGLYCEROL;

AEROBIC EXERCISE; ALDOSTERONE BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ATHEROMA; BICARBONATE BLOOD LEVEL; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGENITAL HEART DISEASE; DRUG EFFECT; DRUG MECHANISM; EDITORIAL; ENDOTHELIUM CELL; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HEART PROTECTION; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; METABOLIC SYNDROME X; OBESITY; POTASSIUM BLOOD LEVEL; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; INSULIN RESISTANCE; LIPOPROTEINS, HDL; QUINOLINES; RISK REDUCTION BEHAVIOR;

EID: 44349112968     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2007.126326     Document Type: Editorial

References (21)

1. JBS 2. Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl 5):v1-52.
2. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
3. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15.
4. Hausenloy DJ, Yellon DM. Targeting residual cardiovascular disease risk: raising high-density lipoprotein cholesterol levels. Heart 2008;94:706-14.
5. Chiesa G, Sirtori CR. Apolipoprotein A-I (Milano): current perspectives. Curr Opin Lipidol 2003;14:159-63.
6. The Coronary Drug Project. Design, methods, and baseline results. Circulation 1973;47:i1-50.
7. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92.
8. Robins SJ, Bloomfield HE. Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials. Curr Opin Lipidol 2006;17:431-9.
9. Verges B. Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD. Curr Opin Lipidol 2006;17:653-8.
10. Nissen SE, Nicholls SJ, Wolski K, et al. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA 2007;297:1362-73.
11. Mackness B, Quarck R, Verreth W, et al. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler Thromb Vasc Biol 2006;26:1545-50.
12. Nofer JR, van der GM, Tolle M, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 2004;113:569-81.
13. Schaefer EJ, Heaton WH, Wetzel MG, et al. Plasma apolipoprotein A-1 absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease. Arteriosclerosis 1982;2:16-26.
14. Food and Drug Administarion. Pfizer stops all torcetrapib clinical trials in interest of patient safety. http://www.fda.gov 2006. (Accessed 29 June 2007.)
15. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22.
16. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620-30.
17. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304-16.
18. Rader DJ. Illuminating HDL - is it still a viable therapeutic target? N Engl J Med 2007;357:2180-3.
19. Patsch JR, Karlin JB, Scott LW, et al. Inverse relationship between blood levels of high density lipoprotein subfraction 2 and magnitude of postprandial lipemia. Proc Natl Acad Sci USA 1983;80:1449-53.
20. Byrne CD, Wild SH, eds. The metabolic syndrome. Chichester: Wiley, 2005.
21. Kodama S, Tanaka S, Saito K, et al. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis. Arch Intern Med 2007;167:999-1008.